Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018992 · ClinicalTrials.gov registry record · Phase 2
Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT01018992 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 267 participants.
The verdict
NCT01018992, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
Interventions
- DRUG Placebo
- DRUG GSK561679
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01018992
The ClinicalTrials.gov registry entry for NCT01018992 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01018992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01018992 about?
NCT01018992 is a clinical study titled "Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder". This study will test the hypothesis of whether an antagonist at the corticotropin releasing factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of post-traumatic stress disorder (PTSD).
What is the current status of trial NCT01018992?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2009-12. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01018992?
The interventions under investigation include: Placebo (DRUG), GSK561679 (DRUG).
Who is sponsoring clinical trial NCT01018992?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.